Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 300

1.

Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study.

De Deyn P, Jeste DV, Swanink R, Kostic D, Breder C, Carson WH, Iwamoto T.

J Clin Psychopharmacol. 2005 Oct;25(5):463-7. Erratum in: J Clin Psychopharmacol. 2005 Dec;25(6):560. Carson, William H [added]; Iwamoto, Taro [added].

PMID:
16160622
2.

Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.

Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, Forbes A.

Am J Geriatr Psychiatry. 2007 Nov;15(11):918-31.

PMID:
17974864
3.

A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.

Streim JE, Porsteinsson AP, Breder CD, Swanink R, Marcus R, McQuade R, Carson WH.

Am J Geriatr Psychiatry. 2008 Jul;16(7):537-50. doi: 10.1097/JGP.0b013e318165db77.

PMID:
18591574
4.

The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.

Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S.

J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.

PMID:
19230981
5.

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.

J Clin Psychiatry. 2002 Sep;63(9):763-71.

PMID:
12363115
6.

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.

Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.

Arch Gen Psychiatry. 2003 Jul;60(7):681-90.

PMID:
12860772
8.

Aripiprazole in the treatment of Alzheimer's disease.

De Deyn PP, Drenth AF, Kremer BP, Oude Voshaar RC, Van Dam D.

Expert Opin Pharmacother. 2013 Mar;14(4):459-74. doi: 10.1517/14656566.2013.764989. Epub 2013 Jan 28. Review.

PMID:
23350964
9.

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.

Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, Carson WH, Marcus RN.

Mov Disord. 2006 Dec;21(12):2078-81.

PMID:
17013906
10.

Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.

Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Greenspan A.

Int J Geriatr Psychiatry. 2005 Dec;20(12):1153-7.

PMID:
16315159
11.

Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.

Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA.

J Clin Psychiatry. 2007 Jan;68(1):111-9.

PMID:
17284138
12.

The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.

Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H.

Int J Geriatr Psychiatry. 2007 May;22(5):475-84.

PMID:
17471598
13.

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T.

Schizophr Res. 2003 Jun 1;61(2-3):123-36.

PMID:
12729864
14.
15.

Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.

Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R.

J Clin Psychopharmacol. 2008 Feb;28(1):13-20. doi: 10.1097/jcp.0b013e3181618eb4. Erratum in: J Clin Psychopharmacol. 2009 Feb;29(1):38.

PMID:
18204335
16.

A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence.

Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J.

J Clin Psychopharmacol. 2008 Feb;28(1):5-12. doi: 10.1097/jcp.0b013e3181602fd4.

PMID:
18204334
17.

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG; Aripiprazole Study Group.

J Clin Psychiatry. 2003 Sep;64(9):1048-56.

PMID:
14628980
18.

Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study.

Findling RL, Nyilas M, Forbes RA, McQuade RD, Jin N, Iwamoto T, Ivanova S, Carson WH, Chang K.

J Clin Psychiatry. 2009 Oct;70(10):1441-51. doi: 10.4088/JCP.09m05164yel.

PMID:
19906348
19.

Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.

Andrezina R, Josiassen RC, Marcus RN, Oren DA, Manos G, Stock E, Carson WH, Iwamoto T.

Psychopharmacology (Berl). 2006 Oct;188(3):281-92. Epub 2006 Sep 5.

PMID:
16953381
20.

Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.

Daniel DG, Currier GW, Zimbroff DL, Allen MH, Oren D, Manos G, McQuade R, Pikalov AA 3rd, Crandall DT.

J Psychiatr Pract. 2007 May;13(3):170-7.

PMID:
17522560

Supplemental Content

Support Center